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ExtERnal Validation of thE SyREon diabEtES ModEl
Zsólyom A.1, Merész G.2, Nagyjánosi L.2, Nagyistók S.2, Nagy B.1, Kaló Z.1, Vokó Z.2
1Eötvös Loránd University, Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary
Objectives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
validation the model’s outcomes needs to be compared to outcomes of cohorts that 
were not used for the modeling exercise. The objective of this study was to demon-
strate the methods and results of the external validation. MethOds: As a first step, 
we identified the applicable clinical trials and cohort studies which had not been 
used to build the model and simulated the patient cohorts for each study according 
to the published demographic, epidemiologic characteristics and treatment pat-
terns. The incidence rates of the predicted and observed outcomes were calculated 
for comparison and the results were evaluated using statistical methods and expert 
opinion. Results: 92 validation analyses were performed. The differences between 
the estimated and measured values of the incidences were within the range of 
44% and -100%. The slope of the fitted linear regression line was 0.5326 while the 
R2 value was 0.6956. The macular oedema submodel presented the best fit and the 
estimated values from the foot ulcer submodel had the lowest accuracy compared 
to values observed in other studies. cOnclusiOns: In overall the model performed 
well, however it frequently underestimated the incidence of the outcomes observed 
in the studies. This is most likely due to the limited information about the patient 
characteristics from the studies under evaluation. In most cases the information 
published about the population characteristics, treatment patterns and effective-
ness were not sufficiently detailed to precisely match the model’s input parameters. 
Without sufficient information average values were used as input parameters, and 
this way the model presumably simulated healthier patient cohorts than the ones 
participated in the studies.
PRM88
diSEntangling EffEctS on fatal and non-fatal caRdioVaSculaR 
EVEntS oVER tiME
Thurston S., Van Hout B.
Pharmerit Ltd., York, UK
Objectives: Within acute coronary syndromes (ACS), the risk of experiencing fatal 
and non-fatal cardiac events is highest immediately after diagnosis and decreases 
over time. Visual inspection of survival curves from pivotal ACS trials suggest three 
potential risk periods. The highest risk (unstable disease) period typically lasts up to 
10 days from diagnosis. Patients then become more stable but are still at a high risk 
of events until approximately 30 days from diagnosis. Beyond 30 days patients are 
considered stable and at a lower risk of events. Different agents may be best suitable 
for different periods and may affect different events. The objective of this research is 
to estimate a model which enables the effects on fatal and non-fatal events follow-
ing an ACS episode to be disentangled and that distinguishes between periods of dis-
ease without accurately knowing how long these periods are. MethOds: A Markov 
model is estimated which distinguishes between three time periods and between 
fatal and non-fatal events. A likelihood function is derived as well as a Bayesian pro-
cedure to estimate the model parameters. The approach is tested using simulated 
data. Subsequently, event free survival data and overall survival data comparing 
ticagrelor with clopidogrel are taken from the Kaplan-Meier curves presented in the 
publication of the PLATO trial and model parameters are estimated based on these 
data. Results: Using simulated data the model mimics the data generating process 
perfectly and the approach seems quite powerful in distinguishing periods and dif-
ferences with patient numbers of 500 and above. cOnclusiOns: When applied to 
the PLATO study we conclude from the model that ticagrelor lowers the probability 
to experience an event in the unstable and stable high risk disease periods.
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a dE noVo EconoMic ModEl to aSSESS thE coSt and Quality of lifE 
conSEQuEncES of an intERVEntion foR lEVodoPa inducEd dySkinESia 
aMongSt PatiEntS with PaRkinSon’S diSEaSE
Bhattacharyya S.1, Sacco P.2, Shirore R.M.1, Sonathi V.1, Thomas S.2
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA
Objectives: Emergence of long-term side effects of treating Parkinson’s disease 
(PD) patients with levodopa, particularly dyskinesia (levodopa induced dyskinesia - 
LID), limit the ability to optimally treat symptoms and consequences of PD. PD-LID 
interferes with performance of activities of daily living, ambulation and balance 
and increases health care costs. There are no approved treatments and no stud-
ies examining cost-effectiveness of an intervention for PD-LID. Objective of the 
present study is to develop a de-novo economic model to identify the value drivers 
for a drug to be cost-effective for treatment of PD-LID. MethOds: The model com-
bines a short-term (6 months) decision tree, to determine initial response to the 
drug, with a long-term Markov approach to model transition of patients across LID 
severity over lifetime. The model classifies LID severity using modified Abnormal 
Involuntary Movement scale (mAIMS) with disease states defined as mild (0-12), 
moderate (13-18) and severe (19-24). Disease state specific costs included costs 
of drug treatments, consultations/visits, paramedical services, laboratory tests, 
radiological examinations, hospitalizations, community/social services and 
unpaid services. State specific utilities were calculated and assigned based on 
literature. Results: The model suggests that initial response to the treatment, 
ability to improve and halt worsening dyskinesia health states are the greatest 
value drivers of the treatment for PD-LID. More than 90% of costs were driven 
by medical costs. A treatment for PD-LID that results in 6-month response rate 
of at least 50%, 25% increase in the probability of dyskinesia improving and 25% 
reduction in the probability of dyskinesia worsening results in a 0.28 QALY gain 
per patient. cOnclusiOns: This economic analysis suggests that a health care 
intervention that could improve the clinical parameters of dyskinesia can have 
significant beneficial impact on costs and utilities. Further studies are required 
vant chemotherapy (ACT). The collection and assessment of data inputs for a U.S. 
economic model evaluating this prognostic will be reported. MethOds: Medline 
and Tuft’s CEA Registry were searched for model parameters using the following 
terms and MeSH headings: NSCLC, adjuvant chemotherapy, recurrence, utilization, 
economics, cost, quality of life, utility, cost-effectiveness/-utility/-benefit. Inclusion 
criteria were randomized controlled trials (RCTs), meta-analyses, heath technology 
assessments, North American and European studies, quality of life analyses, and 
early lung cancer. Results were limited to full text and English articles. We also 
assessed relevant references listed in these articles. Results: The search yielded 
one meta-analysis and 7 RCTs assessing ACT in resected NSCLC. These studies 
report survival (HR 0.75-0.95 favoring ACT), ACT toxicity (30-85% experiencing grade 
3-4 toxicity), and stage distribution (Stage IA-7.6%, IB-29.9%, II-35.3%, III-27.2%). They 
also include disease free survival (HR 0.66-0.93 favoring ACT), but not stratified by 
NSCLC stage. Monthly cost of NSCLC was found in two studies (initial $5,255-11,496, 
continuing $2,602-3,733, terminal $9399-16,470). Two studies reported the U.S. cost of 
ACT toxicity ($4,629-9,516 per grade 3-4 event). Three studies reported utility values 
specific to early NSCLC including one with values related to ACT and toxicity with 
values varying from 0.60 to 0.75. Data reporting current U.S. ACT utilization was not 
identified. cOnclusiOns: Early NSCLC literature contains the majority of data 
inputs necessary for this model. Limitations exist, specifically regarding recurrence 
by stage, current ACT utilization and cost of health care resources. These limitations 
can be overcome using expert opinion, assumptions for guideline adherence and/
or conducting observational studies to inform the model.
PRM85
analySiS of cauSal RElationS in StRokE REgiStRy data
Jakubczyk M.1, Niewada M.2
1Institute of Econometrics, Warsaw School of Economics, Warsaw, Poland, 2Department of 
Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Objectives: Stroke–one of the leading causes of death and disability–represents 
substantial clinical and economic burden. Understanding treatment patterns and 
causative relations may help e.g. to identify outcomes predictors and cost driv-
ers. MethOds: We used Polish Hospital Stroke Registry data on patient baseline 
characteristics (demographics, risk factors, prestroke disability, stroke severity), 
hospital management, treatment outcomes and drugs (pre-admission, during hos-
pitalisation, and prescribed at discharge). We used inferred causation approach that 
deducts causal (not associative) interpretations from patterns of (conditional) inde-
pendence. In this primary analysis we used 5000 observations from 2007/2008 year, 
binary variables and assumed no hidden variables. We used Tetrad 4.3.10-6 with PC 
algorithm. Variables were grouped into five tiers, a priori forbidding some directions 
of causal influence. Large number of variables led us to a restrictive significance 
level (α = 0.0001). Results: New insight can be gained from existence, lack of, and 
the direction of causal relations. Our results: confirmed (without imposing prior 
knowledge) the use of cardiovascular drugs in relation with underlying risk factors 
and natural sequence of drug management (drugs used prior to, in acute stroke 
and at discharge); surprisingly suggested no causal relation between some clinical 
characteristics and drug use (e.g. history of stroke/diabetes and oral anticoagulants) 
or acute stroke treatment (e.g. aspirin, thrombolysis, stroke unit based treatment) 
and mortality/post-stroke disability; determined the causal direction between 
some risk factors (e.g hypertension and diabetes, gender and AF) or patient history 
and prestroke disability (history of stroke or age over 75 and impaired disability); 
could not unambiguously discover the causal-relation between stroke unit based 
treatment and unproven efficacy drugs use. cOnclusiOns: Apart from statistical 
or econometric approach, causal-type reasoning can be used both to confirm the 
intuition, and to detect new patterns in data. Further research should include the 
possibility of hidden variables and try to quantify the causal relations.
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how to SElEct thE Right coSt-EffEctiVEnESS ModEl? a SyStEMatic 
REViEw and StEPwiSE aPPRoach foR tRanSfERRing an ExiSting hEalth 
EconoMic ModEl foR RhEuMatoid aRthRitiS
van Haalen H.G.M.1, Tran-Duy A.2, Boonen A.2, Severens J.L.1
1Erasmus University, Rotterdam, The Netherlands, 2Maastricht University Medical Center, 
Maastricht, The Netherlands
Objectives: To a) to perform a systematic literature review to identify existing 
models for cost-effectiveness analysis of disease modifying anti rheumatic drugs 
in Rheumatoid Arthritis, and b) to develop and test a method for the selection of 
a model that is transferable to the Dutch health care setting by simple adapta-
tion. MethOds: We searched Medline and Embase to identify relevant studies in 
the English language between 1-1-2002 and 31-8-2012. For studies that met the 
inclusion criteria, we applied a 3-step approach in model selection. First, models 
that did not meet all minimal methodological requirements based on the OMERACT 
criteria were excluded. Second, the models were assessed based on their fit when 
transferred to the Dutch health care setting. Transferability factors as published by 
Welte et al., except for those that were deemed transferable by simple adaptation, 
were used for this ranking procedure. Finally, the remaining models underwent 
a general quality check using the Philips checklist. Models showing good fit and 
high quality were considered to be transferable to the Dutch health care setting 
using simple adaptation. Results: The systematic literature search resulted in 498 
papers, which included 33 unique health economic models. Only six models passed 
the OMERACT methodological requirements. Two of these models had imperfect 
transferability fit according to Welte. The remaining four models were, according 
to Philips, of good quality and were expected to be transferable by a simple adapta-
tion. cOnclusiOns: This study introduces a stepwise approach to the identifica-
tion and selection of health economic models that are transferable by a simple 
adaptation. This approach can be applied in various therapeutic areas, provided that 
the minimal methodological requirements are defined accordingly. Availability of 
health economic models coupled with structured model selection could improve 
the efficiency, quality and comparability of health economic evaluations.
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number of scenarios where the EVPI curve takes a different form compared to the 
one illustrated in the typical ‘textbook’ example. For example, when the majority of 
the plotted outcomes are spread over the northern quadrants the traditional EVPI 
peak is absent, and this could be explained by the fact that the reduction in decision 
uncertainty does not outweigh the increased value of opportunity loss. Further, plots 
spread over the eastern quadrants present a maximum EVPI at zero λ which then 
gradually decreases. This study may inform the interpretation of EVPI curves, and 
add value to the analysis of the value of additional research.
PRM93
ModEling MEdication adhEREncE in coMPaRatiVE EffEctiVEnESS 
RESEaRch
Slejko J.F.1, Campbell J.D.2
1University of Washington, Seattle, WA, USA, 2University of Colorado Anschutz Medical Campus, 
School of Pharmacy, Aurora, CO, USA
Objectives: Real-world patients do not exhibit the level of medication adherence 
seen in clinical trials. Hence, the effectiveness of medications in routine practice 
may differ. It is important to understand the manifestations of suboptimal medi-
cation adherence in a population to assess the potential of adherence-improving 
interventions and the real-world value of medications. The objective of our study 
was to compare the clinical outcomes of an adherence naïve framework versus 
a dynamic adherence framework using the case of statins for primary preven-
tion of cardiovascular disease versus no statin use. MethOds: Statin adherence 
was categorized as PDC≤ .20, .20< PDC< .80 and PDC≥ .80 based on a longitudinal 
epidemiological cohort study of US medical and pharmacy claims. Yearly adher-
ence transitions were incorporated into a Markov microsimulation using Treeage 
software. Tracker variables were used to store adherence transitions which were 
then used to adjust probabilities of cardiovascular events (MI, stroke, acute angina) 
over the patient’s lifetime. Statin effectiveness was adjusted between 0% and 
100% of trial-based risk reduction. A total of 10,000 microsimulations were used 
to estimate incremental effectiveness as CV events avoided and quality-adjusted 
life-years (QALYs). Results: In the 10,000-patient statin user cohort simulated 
by the adherence-naïve model, it was estimated that statin use resulted in 1,162 
CV events avoided and 0.39 QALYs gained over a lifetime horizon. The dynamic 
adherence model estimated that 42% of patients exhibited highest adherence, 40% 
exhibited intermediate adherence and 18% exhibited low adherence. This model 
simulated that overall, statin use resulted in 366 events were avoided and 0.18 QALYs 
gained. cOnclusiOns: A Markov microsimulation used to simulate changes in 
patients’ medication adherence over time reveals differential risk reduction and 
effectiveness in terms of CV events and QALYs gained. The framework presented 
here is useful for comparing drugs in which optimal effectiveness and costs may 
be similar, but differential adherence may affect outcomes.
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cauSal analySiS of longitudinal PatiEnt tuRnoVER data at 
hEPatitiS-c
Lang Z., Bacskai M., Tóth E., Rakonczai P.
Healthware Consulting Ltd., Budapest, Hungary
Objectives: In recent years the financer in Hungary (NHIFA) has established a 
detailed and stabile patient turnover database, which reflects time dependent 
changes. Meanwhile, statistical methods of longitudinal data revealing causal 
relationship have been becoming widespread. By these new methods, analyses 
similar to assessment of randomized clinical trials have become available. In 
our research we studied the causal effects of the strategy of treatment, espe-
cially the frequency of retreatment of responder patients on features of status, 
events and costs of patients diagnosed Hepatitis C. MethOds: Causal infer-
ence on longitudinal (e.g. patient path) data is possible using the methods of 
Robins (1999). It makes therapy history exogenous, i.e. independent of the actual 
status of the patient via dynamical, time dependent reweighting of individual 
patient paths. Consequently, patient paths can be analyzed similarly to cohort 
data assessment of randomized clinical trials. The method can be used to con-
firm the results of RCTs. It can substitute RCTs, too, e.g. if RCTs are ethically 
impossible. Results: We obtained by applying Robins’ method that repeated 
combination therapies decreased the risk of liver related complications and the 
development of hepatocellular carcinoma. The method applied to cost analysis 
revealed that despite repeated therapies the costs of newly developed cirrhosis 
and tumor are higher than the corresponding costs of patients with sustained 
viral response. cOnclusiOns: Robins’method is appropriate for measuring the 
causal effects of certain factors of care on patient pathways, especially if patient 
turnover data are supplemented with physiologic, diagnostic and lab information 
found in clinical registers.
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aPPRoPRiatE EVidEncE SouRcES foR PoPulating dEciSion analytic 
ModElS within hEalth tEchnology aSSESSMEnt (hta): a SyStEMatic 
REViEw of hta ManualS and hEalth EconoMic guidElinES
Zechmeister-Koss I.1, Schnell-Inderst P.2, Zauner G.3
1Ludwig Boltzmann Institut for Health Technology Assessment, Vienna, Austria, 2UMIT - 
University for Health Sciences, Medical Informatics and Technology, Hall i. T.; Innsbruck, Austria, 
3Drahtwarenhandlung Simulation Services, Vienna, Austria
Objectives: Decision analytic modellers use numerous types of evidence for 
populating model parameters. Detailed methodological advice on which type of 
data is to be used for what type of model parameter is required. We aim at review-
ing existing HTA manuals and health economic (modelling) guidelines in order to 
gain advice on appropriate evidence sources for populating models. MethOds: 
We identified manuals and guidelines via the International Network of Agencies 
for Health Technology Assessment (INAHTA) and by hand search. We included 
documents from Europe, the USA, Canada, Australia and New Zealand as well as 
transnational guidelines written in English or German. We systematically sum-
to characterize the underlying disease progression parameters and strengthen 
these assessments.
PRM90
oVERViEw of hEalth EconoMic ModElS in tyPE 2 diabEtES MEllituS 
(t2dM); a SyStEMatic litERatuRE REViEw
Charokopou M.1, Sabater F.J.2, Townsend R.3, Roudaut M.2, Verheggen B.G.1
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Rueil-Malmaison, 
France, 3AstraZeneca, Brussels, Belgium
Objectives: To identify and compare economic models developed to evaluate the 
cost-effectiveness of treatments for type 2 diabetes mellitus (T2DM), and their use 
in health care decision-making. MethOds: This research updates two previously 
published systematic reviews. The current systematic literature review was per-
formed according to a pre-defined search strategy and review criteria in six com-
monly used databases from September 2008 to January 2013. In addition, websites 
of Health Technology Assessment (HTA) organizations across nine countries and 
major disease conferences’ proceedings were also reviewed. For each identified 
model, key information was extracted and assessed. Results: Overall, 2262 cita-
tions were identified; 122 full text publications, 169 conference proceedings and 106 
HTA reports met the pre-defined inclusion criteria. Among these, 27 models were 
identified; 6 from full text publications, 18 models from conference proceedings, and 
3 models from HTA reports. Most of the included models applied a similar model 
structure, either using Markov-modelling or micro-simulation techniques, and were 
based on similar key data sources. A key challenge of T2DM economic modelling is to 
appropriately predict the long-term progression of relevant risk factors and translate 
these into clinical and economical consequences of diabetes-related complications. 
In line with previous findings, the UKPDS risk equations were most commonly used 
for the above purposes in the newly identified models. Among published studies and 
HTA submissions, T2DM economic models that are widely published and accepted 
by HTAs include CARDIFF and CORE. cOnclusiOns: The most commonly employed 
models in HTA submissions, namely CARDIFF and CORE, have similar techniques 
to forecast future costs and health outcomes. Hence, the focus for decision makers 
should be to consider the appropriateness of the critical assumptions regarding 
data inputs that impact the results.
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nEtwoRk MEta-analySiS with fRactional PolynoMialS foR REPEatEd 
tRough fEV1 MEaSuRES in coPd: aclidiniuM bRoMidE 400 μg bid VERSuS 
tiotRoPiuM 18 μg Qd
Karabis A.1, Jansen J.P.2, Lindner L.3
1Mapi, Houten, The Netherlands, 2Mapi / Tufts University School of Medicine, Boston, MA, USA, 
3Almirall UK, Uxbridge, UK
Objectives: To estimate the relative efficacy of aclidinium bromide 400 µg 
BID (AB400), to tiotropium bromide 18 µg QD (TIO18) by means of lung function 
in patients with COPD, within the first 24 weeks of treatment and illustrate the 
repeated measures network meta-analysis (NMA) models. MethOds: A system-
atic literature search using a predefined strategy in MEDLINE, EMBASE and the 
Cochrane Library identified 16 unique placebo-controlled RCTs reporting FEV1 
trough: TIO18 (n= 13) and AB400 (n= 3). The development of trough FEV1over time 
for AB400, TIO18 and placebo (PLA) was modeled with fractional polynomials, and 
the difference between the parameters of these polynomials within a trial were 
synthesized across studies with a Bayesian NMA. This type of NMA allows for the 
simultaneous analysis of outcomes at multiple time points. The within-trial cor-
relation was not available from the publications of the included studies, and as 
such a sensitivity analyses was performed assuming different values for the cor-
relation. Results: Given the fractional polynomial parameters obtained with the 
NMA model, the corresponding treatment effects over time for AB400 vs TIO18, 
AB400 vs PLA and TIO vs PLA were estimated. The model with t-0.5and log(t) had 
the best fit according to the deviance information criterion (DIC). These polynomi-
als and within study correlation were used for the modeling of the outcomes over 
time. AB400 is equally efficacious compared to TIO18 during the first 24 weeks, as 
the 95% CrI of the difference in CFB between the treatments includes zero while 
the mean is < 15mL. Furthermore, the probability that each treatment was best was 
calculated as a function of time. cOnclusiOns: This analysis demonstrates the 
use of the proposed NMA models and suggests that maintenance treatment with 
AB400 results in comparable improvements in lung function, as TIO18 in COPD 
patients over a 24 weeks period.
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EVPi cuRVES in PRacticE
Jeppsson K.1, Posnett J.2, Carlqvist P.3
1HERON Evidence Development Ltd., London, UK, 2Heron Evidence Development, Ltd., London, UK, 
3Heron AB, Stockholm, Sweden
When making decisions about the allocation of scarce health-care resources it’s 
not only important to consider the estimated cost-effectiveness (CE) with current 
evidence, but also the value of additional research. Expected value of perfect infor-
mation (EVPI) is the amount a decision maker should be willing to pay to eliminate 
uncertainty surrounding the decision about which option is optimal for different 
levels of the CE threshold (λ ). Although EVPI analysis is being requested increasingly 
by reimbursement agencies there is still limited literature on the interpretation 
of EVPI curves. The typical ‘textbook’ example represents just one of the possi-
ble shapes that the curve can take. Objectives: To explore and explain different 
shapes of EVPI curves based on the position of alternative treatment choices on 
the incremental cost-effectiveness plane. MethOds: A hypothetical probabilistic 
decision model was developed in which two interventions were compared. Key 
input parameters were varied to force the model outcomes into different quad-
rants on the incremental CE plane. The population EVPI, based on a hypothetical 
number of future patients and the estimated lifetime of the new intervention, was 
plotted. Results And cOnclusiOns: The result of this study demonstrates a 
